Document is current
Any future updates will be listed below
-
Authors
Urban, Nikolaus
Neidhart, Thomas
Grabmeier-Pfistershammer, Katharina
Touzeau-Roemer, Veronique
Schmidt, Kaspar Laurenz
Strassl, Robert
Weninger, Wolfgang
Willinger, Birgit
Bauer, Wolfgang Michael
Chromy, David https://orcid.org/0000-0002-1807-8258
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 12 October 2024
Accepted: 10 January 2025
First Online: 2 March 2025
Conflict of interest
: N. Urban received travel support from ViiV Healthcare. K. Grabmeier-Pfistershammer served as a speaker and/or consultant and/or advisory board member for ViiV, Gilead, and received travel support from ViiV Healthcare, and Gilead. B. Willinger served as a speaker for Gilead and advisory board member for MSD. W. Weninger served as a speaker, consultant and/or advisory board member for LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. W.M. Bauer served as a speaker and/or consultant and/or advisory board member for AbbVie, ViiV Healthcare and Takeda, and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead. D. Chromy served as a speaker and/or consultant and/or advisory board member for AbbVie, Gilead, and MSD, and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead. T. Neidhart, V. Touzeau-Roemer, K.L. Schmidt and R. Strassl declare that they have no competing interests.
